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ABSTRACT
Introduction Researchers, policy- makers and healthcare 
professionals often stress the importance of an early 
dementia diagnosis. Empirical evidence, however, is 
scarce leading to a lack of consensus on the necessity of 
diagnosing dementia early. We emphasise the need for 
a ‘timely’ diagnosis, that is, one that occurs at the right 
moment for a person with memory complaints and his/
her significant other. As the optimal timing differs between 
individuals, the implementation of shared decision making 
(SDM), preferably by the general practitioner (GP), as the 
start of a diagnostic trajectory, could help to determine 
this timely moment. SDM, however, is rarely practised with 
respect to dementia diagnoses. Therefore, in the context 
of the Shared Decision- Making regarding Dementia 
Diagnosis project, a patient decision aid (PtDA) for ‘timely’ 
dementia diagnosis in general practice will be developed. 
This protocol will describe the planned before and after 
evaluation of its implementation.
Methods and analysis In a mixed- methods pilot study, 
we will investigate decision- making processes and 
experiences regarding a diagnostic trajectory before and 
after the introduction of a PtDA for people with memory 
complaints, their significant others and their GPs. The 
‘before group’ will receive diagnostics as usual from their 
GPs. The ‘after group’ will use the PtDA. We expect the 
PtDA to increase the level of SDM and to contribute to a 
timely and personalised diagnostic trajectory. Data will be 
collected using semistructured interviews, questionnaires 
and information retrieved from people with memory 
complaints’ medical records.
Ethics and dissemination This study protocol was 
approved by the Medical Review Ethics Committee of 
the Maastricht University Medical Centre. The findings 
will be published in peer- reviewed international journals 
and presented at conferences. This study was funded by 
the public funded Dutch Research Institute for Care and 
Medical Sciences (ZonMw).
Trial registration number NCT04531956.
INTRODUCTION
As a result of a global increase in life expec-
tancy, the prevalence of cognitive impairment 
and probable dementia will likely rise.1 Older 
people commonly express anxieties about 
loss of cognition and of being diagnosed with 
dementia.2 This is presumably stimulated 
by the media and Alzheimer associations 
as they increase awareness of the dementia 
burden.3 As a consequence, general practice 
will increasingly encounter these worried 
people and their significant others. Many 
clinicians, researchers and Alzheimer asso-
ciations stress the importance of assessing 
memory complaints early. In some countries, 
discussions about screening asymptomatic 
people above 65 years for dementia symp-
toms are ongoing to be able to diagnose 
dementia in an early stage.4 Early diagnosis 
refers to disclosure as soon as clinical tools 
indicate dementia.5 6 However, whether this 
Strengths and limitations of this study
 ► The mixed- methods design will generate multiple 
perspective insights on decision- making processes 
and experiences regarding a diagnostic trajectory 
of people with memory complaints, their significant 
others and their general practitioners (GPs). Given 
the complexity of a shared decision- making (SDM) 
intervention integrating qualitative data and quan-
titative data will reveal the working mechanisms of 
the SDM intervention.
 ► Semistructured interviews with people with memory 
complaints, their significant others and their GPs will 
give an in- depth understanding of decision- making 
processes and mutual experiences regarding an 
(early) diagnostic trajectory.
 ► A convenient consecutive sample of patients is 
used, in which differences in baseline characteris-
tics could influence the outcome measures.
 ► GPs included in the study know an intervention that 
should improve SDM will be implemented. In the 
preintervention group, they are asked to give care 
as usual; however, it could be that they change their 
behaviour because they are primed by our study.
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approach leads to improvement in terms of the health 
and well- being of people with memory complaints 
remains debated.7–9 On the one hand, early identification 
of dementia syndrome could enable people with memory 
complaints and their significant other(s) to plan their 
future care and life.6 10–12 Also, future interventions could 
potentially delay the progression of the disease.6 13 14 
Simultaneously, it may reassure a person with memory 
complaints that indications of incipient Alzheimer’s 
disease are not present. On the other hand, early iden-
tification of dementia has disadvantages. Diagnosing 
people with dementia early, while no effective cure is 
available, raises many ethical, healthcare and economic 
questions.14 15 That is, an early identification could be 
burdensome, anxiety- provoking, stigmatising and is 
even harmful when it raises false expectations.6 14 Many 
healthcare professionals, therefore, have expressed their 
doubts about an early diagnostic trajectory.16 17 Addition-
ally, screening asymptomatic people above 65 years old 
in primary care has shown neither harms nor benefits in 
terms of quality of life, depression or anxiety symptoms 
and risks of not acting on subjective memory complaints 
in an early stage might be underestimated because of the 
under- reporting of these complaints.18 19
Taking all these arguments together, early stage identi-
fication of dementia or delaying/deferring identification 
could be considered a preference- sensitive decision.16 17 
That is, the advantages and disadvantages of a diagnostic 
trajectory are, presumably, valued differently by each 
person with memory complaints and his/her significant 
other. Perceptions about dementia and beliefs about 
possible treatment play a role in how these advantages 
and disadvantages of diagnostic assessment for dementia 
are valued and eventually which decision about diag-
nostic assessment is made.20 In this respect, it is surprising 
that the preferences of people with memory complaints, 
their significant others, and clinicians regarding early 
identification of dementia have not been fully explored. 
It is well studied that personal preferences influence 
healthcare decisions and, consequently, impact the well- 
being of those affected by these decisions.16 21 22 The 
potential advantages and disadvantages of identification 
of dementia and patients and their significant others’ 
preferences therein should thus ideally be explored at 
the start of the diagnostic trajectory.6 14 17 23 A preferred 
setting to discuss this is a general practice as the general 
practitioner (GP) is generally the first clinician visited. 
Additionally, the GP has often known the person for many 
years and can recognise any significant changes in the 
person’s cognitive functioning. Last, it corresponds with 
GPs’ views on this topic as most of them value a ‘timely’ 
diagnosis over an ‘early’ diagnosis.16 A timely diagnosis 
implies that a diagnostic process should be initiated at the 
right time for the person with memory complaints and 
their significant others to meet their expectations, needs, 
and preferences.21 One way to achieve a timely diag-
nosis for the person with memory complaints and his/
her significant other is shared decision making (SDM). 
SDM is generally defined as a dynamic approach in 
which a healthcare professional informs a patient about 
the available options and explores the patient’s prefer-
ences, with the ultimate goal of agreeing on a specific 
decision.24 This process requires a continual counselling 
dialogue between professional and patient and/or proxy 
decision- maker (eg, significant other).25 In the case of 
early identification of dementia, implementing SDM in 
general practice, at the start of the diagnostic trajectory, 
could ensure concordance of diagnostic procedures with 
patients and their significant others’ preferences.6 26–28 
Nevertheless, implementing SDM in clinical practice has 
proven challenging. That is, professionals often express 
the inability to give a complete and balanced overview 
of the advantages/disadvantages of a medical decision, 
because of a lack of skills,tools or time.29 Moreover, clini-
cians oppose to SDM implementation as they think they 
already apply SDM in daily practice or assume that their 
patients do not want to be involved in decision making.30 
Implementing SDM specific for people with memory 
complaints is additionally expected to be challenging 
because people with memory complaints and their signif-
icant others sometimes have conflicting views regarding 
initiating a diagnostic process due to denial, fear or a 
lack of perceived need.31 Moreover, participation in SDM 
requires certain cognitive skills that people with memory 
complaints might be lacking32
Patient decision aids (PtDAs) have proven to overcome 
some of these barriers and improve SDM implementation 
in general practice33 34 by providing information about the 
available clinical options, they facilitate discussions about 
their advantages and disadvantages resulting in better 
patient engagement in the decision- making process.33–36 
They are effective in achieving informed preferences and 
in increasing the number of decisions that are in line with 
patients’ preferences.36 37 The use of PtDAs is also associ-
ated with decreased decisional conflict: the state in which 
a person is uncertain about a decision that is associated 
with certain risks and different outcomes, as could be the 
case in deciding on an (early) diagnostic trajectory in case 
of memory complaints.36–38 Even though decision aids 
could facilitate a personal, patient- centred approach in 
the diagnostic trajectory of memory complaints, they are 
rarely applied.27 28 33 34 An exception is a recently devel-
oped PtDA for applying biomarkers in memory clinics.39 
However, to find the right timing to start the diagnostic 
process and to optimise conversations about the advan-
tages and disadvantages of early identification dementia, 
a PtDA for use in the general practice is needed.6 14 17 23 
The objective of the Shared Decision- Making regarding 
Dementia Diagnosis (S- DeciDeD) study is, therefore, to 
develop, implement and evaluate a PtDA using a system-
atic approach for use in general practice, one which facil-
itates SDM regarding a timely diagnostic trajectory for 
people with memory complaints.
This paper aims to describe the study protocol for the 
pilot evaluation of the S- DeciDeD PtDA for people with 
memory complaints in general practice.
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Study objectives
The study objectives are to (1) describe and explore the 
decision- making process (eg, perceived SDM by people 
with memory complaints and their GPs) before and 
after implementing a PtDA and to (2) assess to which 
extent and how a PtDA influences the decision- making 
process for a diagnostic trajectory in people with memory 
complaints and their significant others. We expect that 
implementing a PtDA in general practice will lead to 
higher levels of perceived SDM.
METHODS
Study design
This pilot trial will use a before- and- after mixed- methods 
design. In the before group (BG), GPs will execute care 
as usual in the decision- making process for a diagnostic 
trajectory for memory complaints. In the after group 
(AG), a PtDA will be added to the decision- making 
process provided by the GP. The rationale for this design 
is as follows. First, it maximises comparability between 
GPs as they will participate in both the before and after 
period of the study. Second, GPs will be able to reflect 
on their practice preintervention and postintervention. 
Third, it allows and facilitates the implementation of the 
PtDA in all interested GP practices. Fourth, the mixed- 
methods approach is used to gain a broad and in- depth 
understanding of the issues important for people with 
memory complaints, their significant others, and the 
GPs involved in the decision- making process.40 We are 
taking this approach to fully unravel the complexity of 
the decision- making process for a diagnostic trajectory 
for memory complaints and of the PtDA.6 29 30 Last, the 
use of a pilot trial allows us to explore if the proposed 
methods are feasible to assess decision- making processes 
in general practice before and after implementation of a 
PtDA. This could help plan and execute a larger defini-
tive trial to investigate the effectiveness of using a PtDA in 
general practice for people with memory complaints and 
their significant others.41
Setting
The study was developed by Maastricht University Medical 
Centre (MUMC+) in close collaboration with Radboud 
University Medical Center Nijmegen (Radboudumc 
Nijmegen). The participating GPs, people with memory 
complaints and their significant others will be recruited 




Before the start of the study, a client panel of the 
Alzheimer Centre Limburg (ie, a panel consisting of 
people with dementia and their significant others) was 
asked to reflect on the research design. During the study, 
people with memory complaints and their significant 
others will be closely involved in the development and 
implementation of the PtDA.
Recruitment and study participants
First, the researchers will approach GPs working in the 
south- eastern part of the Netherlands with an informa-
tion letter about the study. No specific inclusion and 
exclusion criteria have been formulated for the GPs. 
GPs who want to participate will be asked to return an 
application form to the research team. Subsequently, the 
research team will then provide participating GPs with 
study material (patient application forms, information 
letters, and informed consent forms). GPs will be asked 
to recruit patients with memory complaints during an 
inclusion period of 6 months in both the BG and AG. In 
the BG, the GPs will inform potential participants about 
the study after a decision about a diagnostic trajectory 
(ie, to wait and see, undergo diagnostic testing by the GP, 
or referral to a medical centre) has been made. Patients 
can be included up to a maximum of 3 months after a 
decision has been made. Significant others of people 
with memory complaints will be asked to participate as 
well; their participation is preferred, but not required. 
Significant others are obtained by asking the person with 
memory complaints to name someone closely involved 
in the decision- making process on diagnostic assessment 
(eg, spouse, child, other close relatives or friends) The 
inclusion and exclusion criteria of the study are shown 
in box 1. Participants are initially assessed for eligibility 
by their GP. If an eligible participant is interested in the 
study, the GP will send his/her contact details to the 
researchers. The researchers will contact the potential 
participant to provide detailed information about the 
study. Eligible participants will sign informed consent 
forms before participation. The inclusion/consent proce-
dure in the AG will be finalised based on the developed 
intervention in a later stage of the study. Data collec-
tion in the BG is expected to last from January 2021 to 
September 2021. In the AG, data collection is expected 
to last from October 2021 to June 2022. Patients will be 
selected using convenience sampling. Patients will receive 
a small incentive for their participation as well as GPs.
Handling of personal data will be in accordance with 
the Dutch Personal Data Protection Act and Medical 
Research (Human Subjects) Act.
Intervention
The intervention will consist of implementing a PtDA 
in general practice. The PtDA will be developed in line 
with the systematic development process specified by 
the International Patient Decision Aids Standards.42 The 
development of the PtDA runs parallel to the inclusion 
of participants in the BG. Before the start of the develop-
ment process, we will explore stakeholders’ opinions and 
experiences with the decision- making process and map the 
current diagnostic trajectory in general practice. This will 
be done by conducting interviews with patients, significant 
others, and GPs about their experiences and considerations 
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in the (early) diagnostic trajectory. Furthermore, data on 
reasons for encounter, diagnostic procedures and refer-
rals in general practice will be analysed with help of the 
practice- based research network Family Medicine Network 
(FaMe- net).43 44 Lastly, a systematic integrative review will 
be conducted about the preferences and needs of people 
with memory complaints, and their significant others, and 
GPs regarding the timing of dementia diagnosis. For the 
development of the PtDA, we will partner with people 
with memory complaints, their caregivers and GPs (ie, 
a steering group). With help of this steering group, the 
scope of the PtDA will be refined and their feedback will 
guide the content and format of prototypes. This will be 
done in several workshops with the steering group.
Finally, the patient decision- aid will be pilot- tested with 
help of a test panel. Its usability, language and format will 
be rated. Based on the pilot, GPs will be instructed on 
how to best deliver the PtDA to the patient, these instruc-
tions will be personalised in case needed. More informa-
tion on the development of the PtDA can be found in 
online supplemental appendix.
Outcome measures
This before- and- after study will focus on accomplishing a 
complete understanding of the decision- making process 
for a diagnostic trajectory in case of memory complaints 
before and after implementing a PtDA in the general 
practice. To accomplish this complete understanding, 
five aspects will be focused on: (1) the course of the 
decision- making process, (2) outcome of the decision- 
making process, (3) experiences during the decision- 
making process, (4) the perceived SDM and preferences 
therein and (5) decisional conflict (see table 1). In the 
most cases, a significant other is closely involved in the 
decision regarding the diagnostic trajectory. There-
fore, this study will map the experiences and decisional 
conflict of both the person with memory complaints and 
a significant other (preferably separate interviews will be 
conducted). Interviews will be conducted by a trained 
research assistant or one of the main researchers. Qual-
itative measures integrated with quantitative measures 
will be used to achieve cross- validation or triangulation of 
data from multiple sources40 :
1. The course of the decision- making process will be ex-
plored through retrospectively studying the number 
of consultations needed to achieve the final decision 
and through studying ‘free text’ notes in the med-
ical record of the person with memory complaints. 
Data from these notes will be extracted with a data 
extraction form designed to extract signs of shared- 
decision making. The data extraction sheet is based on 
the SDM model.45
2. The outcome of the decision- making process, that is, 
to wait and see, undergo diagnostic testing by the GP, 
or referral to a medical centre will also be obtained 
from the medical record of the person with memory 
complaints.
3. The decision- making process in general practice will 
be explored with semistructured interviews (by tele-
phone or face to face) with people with memory com-
plaints and their significant others. Questions will fo-
cus on their experiences, considerations, preferences 
and expectations during the decision- making process. 
Preferably patients and their significant others are in-
terviewed individually.
4. To assess SDM during the decision- making process, 
people with memory complaints (and their significant 
others) will be interviewed about their experienced 
level of SDM and preferences regarding SDM. Their 
GPs will be asked to complete questionnaires about the 
level of SDM and their self- efficacy regarding SDM.
1. The level of SDM will be assessed by using the Dutch 
version of the SDM Questionnaire- Doc (SDM- Q- 
Doc).46 This 9- item SDM- Q- Doc focuses specifi-
cally on the GP’s perspective of the SDM process. 
The questionnaire has six- level response options 
(0=completely disagree to 5=completely agree), 
where higher scores indicate more SDM.46 The scale 
has been shown to have good internal consistency 
and acceptance and acceptable- to- good convergent 
validity in a sample of physicians.46
2. Self- efficacy regarding SDM will be assessed via a 
Visual Analogue Scale.47 GPs have to indicate the 
Box 1 Inclusion and exclusion criteria of the Shared 
Decision- making regarding Dementia Diagnosis study
Person with memory complaints
Inclusion criteria
 ► Person has visited the general practitioner because of memory 
complaints no longer than 3 months ago (noticed by the person, a 
significant other and/or the general practitioner).
 ► Person is above the age of 60.
 ► Person is able to complete baseline assessments.
 ► Person must have the decisional capacity to provide informed 
consent.
 ► Person must give written informed consent prior to participation.
Exclusion criteria
 ► Person has communication/language/comprehension/literacy or 
(severe) hearing problems.
 ► Person has had a severe mental illness in the last 12 months, such 
as schizophrenia, depression, or a bipolar disorder not otherwise 
specified.
 ► Person has a life- threatening comorbid illness.
Significant other (if present)
Inclusion criteria
 ► Significant other is able to complete baseline assessments.
 ► Significant other must have the decisional capacity to provide in-
formed consent.
Exclusion criteria
 ► Significant other has communication/language/comprehension/lit-
eracy or (severe) hearing problems.
 ► Significant other has had a severe mental illness in the last 12 
months, such as schizophrenia, depression or a bipolar disorder not 
otherwise specified.
General practitioners
No inclusion or exclusion criteria.
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level of SDM during the last consultation with the 
person with memory complaints (anchored by—
no SDM—complete SDM) and their self- efficacy 
regarding SDM (anchored by—not competent at 
all—very competent) after the last consultation.
5. Decisional conflict of people with memory complaints 
and their significant others will be explored in a sem-
istructured interview (by telephone or face to face). 
The questions will focus on uncertainty regarding the 
choice made, factors contributing to this uncertainty 
and the perceived effectiveness of the decision.
Other measures
6. A baseline questionnaire in combination with the med-
ical record of the person with memory complaints will 
be used to assess demographic features of people with 
memory complaints and their significant others.
7. The characteristics of GPs that will be collected are the 
location of the general practice (rural or urban), the 
composition of the general practice (number of GPs 
and general practice- based nurses), years of experi-
ence each GP has with the population (patients with 
memory complaints), gender and age.
Sample size
Given the dependence between patients and their GPs 
in our sample, clustering of patients per GP was taken 
into account in sample size calculations. Clusters were 
expected to include at least two people with memory 
complaints and intraclass correlation to be 0.05 or 
lower.48 49 To achieve power of 0.8 and two- sided testing at 
0.05, 35 GPs are required.
We, therefore, aim to include between 30 and 40 GPs 
in our study which seems to be a realistic number based 
on a previous (comparable) study.50 This should result in 
recruiting around 70 patients (with or without significant 
other).
For the qualitative component of the study, it is expected 
that interviews with 15–30 patients, with or without their 
significant other will be sufficient to reach data saturation 
(ie, the point at which interviews reveal no new informa-
tion or insights). Participants will be asked to participate 
in an interview based on the outcome of the decision- 
making process (ie, to wait and see, undergo diagnostic 
testing at the GP, be referred to a medical centre for 
advanced diagnostic testing). In this way, we can ensure 
that each ‘choice category’ is represented in the selective 
sample. From those patients not selected for the inter-
views, only qualitative data from their medical journals 
(eg, free text notes) will be analysed. This procedure will 
be the same in the BG and AG.
Table 1 Overview of the measures, components, methods and instruments of the S- DeciDeD study
Measure Components Method and instruments
1.Course decision- making process 1. No of consultations
2. ‘Free text’ notes in medical record regarding 
the decision- making process
1. Medical record PMC
2. Thematically analysing medical 
record PMC with help of a data 
extraction sheet
2.Outcome of the decision- making process Final decision (ie, to wait and see, undergo 
diagnostic testing by the GP, or referral to a 
medical centre)
Medical record PMC
3.Decision- making process in general 
practice
1. Experiences, considerations, expectations 
and preferences PMC




4.Shared decision- making (SDM) 1. Experience SDM PMC
2. Experience SDM SO
3. Level of SDM indicated by GP




3. SDM- Q- Doc
4. Self- efficacy VAS
5.Decisional conflict 1. Decisional conflict experienced by PMC
2. Decisional conflict experienced by SO
1. Semistructured interview
2. Semistructured interview
6.Characteristics of people with memory 
complaints and significant others
Demographic data 1. Baseline questionnaire with 
questions on demographics
2. Medical record PMC
7.Characteristics GP Contextual factors related to the GP GP practices will be contacted to 
provide information on location, years 
of experience GP, and the composition 
of the general practice.
GP, general practitioner; PMC, person with memory complaints; S- DeciDeD, Shared Decision- making regarding Dementia Diagnosis; 
SO, significant other; VAS, Visual Analogue Scale.
by copyright.
 on O













pen: first published as 10.1136/bm








Descriptive analyses will be conducted on the socio-
demographic characteristics of people with memory 
complaints, their significant others and GPs. To assess 
the decision- making process, descriptive analyses will be 
conducted on: the number of consultations before the 
final decision, final decision (ie, number of decisions in 
each ‘choice category’), level of SDM and level of self- 
efficacy regarding SDM as indicated by GPs. Furthermore, 
multiple regression analysis will be performed to inves-
tigate: (1) whether sociodemographic characteristics or 
characteristics of the decision- making process are related 
to the outcome of the decision- making process or to the 
level of SDM and (2) whether the level of SDM is associ-
ated with the outcome of the decision- making process. 
A random effect multilevel analysis will be used to assess 
changes in the decision- making process before and after 
implementing the PtDA while taking clustering at the GP 
level into account. Baseline characteristics will be added as 
confounders in case of observed differences in the before 
and AG. Since the participation of significant others is 
not required, differences in outcome measures between 
participants participating with and without significant 
others will be explored. In case differences are found, 
this will be taken into account in the main analysis. Inte-
gration of these analyses with qualitative measures will 
help explain these results. All analyses will be conducted 
using SPSS version 25. In case of missing data, GPs will be 
contacted to retrieve the missing values.
Qualitative analysis
Qualitative methods will be used to analyse data regarding 
experiences in the decision- making process, SDM and 
decisional conflict. Interviews will be audiotaped and tran-
scribed verbatim. Because of the explorative nature of the 
study, we will conduct an inductive thematic analysis.51 Two 
researchers will separately code transcripts of the interviews. 
The thematic analysis will consist of an iterative process of 
several steps. First, two researchers will familiarise themselves 
with the data by (re) reading the transcripts and creating 
initial codes. Second, codes will be clustered into categories 
(axial coding), when they describe or relate to the same 
phenomena. Third, codes can be renamed or reassigned, 
after which categories can be combined and themes refined 
(selective coding). Fourth, the categories and themes will be 
discussed with the research team and will be re- evaluated. 
As a final step, consensus will be reached on the categories 
and main themes’ relevance and meaning.52  Atlas. ti will 
be used to support the analyses. Data from the interviews 
with people with memory complaints and their significant 
others will be incorporated in the same thematic structure. 
This way we can show possible differences and similarities 
in their experiences of the decision- making process. The 
recommendations outlined in the COnsolidated criteria for 
REporting Qualitative research (COREQ) criteria will be 
followed in reporting the results.53
Mixed model analysis
Integration of quantitative and qualitative research 
methods will be applied during data collection as well as 
during analyses. During the data collection, attention will 
be paid to ‘building’ and ‘merging’.54 Building will be 
applied by selecting patients for semistructured interviews 
based on quantitative data such as age, gender, and the 
final outcome of the decision- making process. Merging 
will be applied through tailoring topic lists for the semi-
structured interviews to the personal situation of patients 
and their significant others, a task which will be accom-
plished with the help of information from their medical 
record. During data analyses, ‘merging’ and ‘embedding’ 
will be applied (ie, qualitative data will be used to explain 
identified patterns in quantitative outcome measures 
which will provide insight into the working mechanisms 
of the PtDA).55 56 Both the qualitative and quantitative 
data sets will be analysed independently and concur-
rently. Subsequently, the data will be assessed for comple-
mentarity. This will include using the qualitative data to 
achieve a more in- depth and complete understanding 
of the course of the decision- making process before and 
after implementing a PtDA.
In conclusion, this study aims to examine the decision- 
making process regarding starting a diagnostic trajectory 
for memory complaints before and after implementing a 
PtDA. Through using a mixed- method approach, we hope 
to unravel the complexity of this decision- making process 
and investigate the potential impact of implementing a 
PtDA on this process. The results of this pilot study could 
help plan and execute a larger definitive trial to investi-
gate the effectiveness of using a PtDA in general practice 
for people with memory complaints and their significant 
others. Specifically, the results will inform to which extent 
these study methods and procedures are feasible to inves-
tigate decision- making processes in general practice.
Ethics and dissemination
Care as usual will most likely not be influenced in the BG of 
the S- DeciDeD project. Only a small- time investment will be 
required from GPs and patients: 5 min for completing the 
questionnaires and twenty minutes for participating in the 
interview. The protocol of the BG has been approved by the 
Medical Review Ethics Committee (MEC) of the MUMC+ in 
the Netherlands, number 2018–0333. Data collection in the 
BG will start at the beginning of 2021.
The protocol for the AG will be submitted to the MEC 
after the development of the PtDA as judgement should 
include full information on this novel intervention. The 
S- DeciDeD project is part of the national Memorabel 
programme funded by ZonMw. Any important protocol 
modifications will be submitted to the MEC of Maastricht 
University and ZonMw for approval.
Furthermore, as Maastricht University aims to 
become a Findable, Accessible, Interoperable and 
Re- usable university, the data will also be published on 
DataverseNL (https:// dataverse. nl/). This is a website 
where researchers can upload their anonymous data with 
by copyright.
 on O
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restricted access, which allows other researchers to use 
the data or replicate the findings after receiving permis-
sion from the S- DeciDeD project. Finally, the findings will 
be published in peer- reviewed international journals and 
presented at conferences and in one dissertation.
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Development patient decision aid 
 
The patient decision aid will be developed in collaboration with people with memory 
complaints, their significant others, and GPs, in line with the International Patient Decision 
Aid Standards (IPDAS).[42]The decision aid will be developed, implemented in general 
practice, and evaluated. This will be done in three phases; (1) exploration phase, (2) 
development phase, (3) evaluation phase (see Figure 1). The exploration and development 
of the patient decision aid partly run parallel to the inclusion of participants in the before 
group, rendering an optimal/efficient use of time.       
 
Exploration phase 
During the exploration phase, data will be collected and analysed as input for the patient 
decision aid. Interviews will be conducted with patients and their significant others that are 
recruited via a hospital-based memory clinic and with general practitioners. More 
information on these interviews and the inclusion procedure can be found in the next 
section. Furthermore, data from the practice-based research network Family Medicine 
Network (FaMe-net) of the Department of Primary and Community Care (ELG) at the 
Radboud University Medical Centre will be analysed to provide input for the development of 
the patient decision aid. FaMe-net consists of 11 Dutch general practices in three 
geographical regions (62.000 listed patients).[43,44] FaMe-net general practitioners 
systematically register data on the reason for encounter, diagnostic procedures, diagnoses, 
interventions, and referrals.[43,44] This data will be used to map the current decision-
making process and diagnostic trajectory in general practice for people with memory 
complaints. Additionally, a systematic integrative review will be conducted about the 
preferences and needs of people with memory complaints, and their significant others, and 
GPs regarding the timing of dementia diagnosis. 
 
Development phase  
During the development phase, the patient decision aid will be developed with help of a 
steering group. This group will consist of people with memory complaints, caregivers, and 
general practitioners.  During several workshop sessions their views, needs, and feedback 
will be incorporated on defining the scope of the patient decision aid. They will furthermore 
be asked to provide feedback on proposed prototypes by the research team. Prototypes will 
be adjusted according to their feedback. The final prototype will be pilot-tested with help of 
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Evaluation phase 
During the evaluation phase, the feasibility of the patient decision aid will be tested. Data to 
assess this feasibility will be collected in the after group of the before-after pilot study (see 
Figure 1). Also, online users of the patient decision aid will be asked to complete the Ottowa 
Acceptability Measures questionnaire. These users (N = 40-60) will be asked to rate the 
length, clarity, fairness, and helpfulness of the decision aid on a 4-or 5-box scale. 
 
 
Study population and data collection to inform development patient decision-aid 
 
Memory clinic group 
People with memory complaints who were referred to a memory clinic for advanced 
diagnostic testing will be asked to participate in our study. These people will be recruited 
through the memory clinic of the MUMC + in Maastricht.  
Inclusion procedure 
Potential participants are asked to participate in the study before their first appointment at 
the memory clinic. A member of the treatment team of the memory clinic will inform 
potential participants about the study. If the participant is interested the researchers will 
contact the potential participant to provide detailed information about the study.  
 
The following data from these participants will be used as input for the development of the 
patient decision aid; 
1. Medical record 
Medical journals with the code ‘memory complaint’ and a possible referral letter to a 
memory clinic will be thematically analysed to assess the decision-making process. 
2. Experiences and considerations in the decision-making process regarding the 
diagnostic assessment of memory complaints at their GP 
People with memory complaints and their significant others will be asked to participate 
in a semi-structured interview (by telephone).  
 
General practitioners 
General practitioners participating in the pilot study and the general practitioners of the 
people recruited via the hospital-based memory clinic will be asked to participate in a semi-
structured interview (by telephone). Interviews will focus on their preferences, experiences, 
and opinions regarding an (early) diagnostic trajectory of memory complaints and the role of 
shared-decision making therein. 
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Figure 1. S-DeciDeD study overview.                                                                                                                                                                                                                                                                                                     
Note. BG = Before Group, AG = After Group, PMC = Person with Memory Complaints, SO = Significant Other, GP = General Practitioner, PtDA = patient decision aid 
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